Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds

domin_domin This article was coproduced with Chuck Walston. With the spinoff of its consumer-health segment, now known as Kenvue (KVUE), Johnson & Johnson (NYSE:JNJ) is now focused on its pharmaceuticals and medical devices businesses. Pharmaceuticals now generate just under two-thirds of the company’s revenue, with the latter segment hauling in the remainder. With a solid pipeline of cancer, immunology, and neurology drugs, along with a market leading medical device portfolio, management believes JNJ o ...